

 참고 문헌

1. Al-Fadhli R, Sylvestre C, Buckett W, Tan SL, Tulandi T. A randomized trial of superovulation with two different doses of letrozole. *Fertil Steril* 2006;85:161-4.
2. Al-Inany HG, Abou-setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. *Reprod Biomed Online* 2007;14:640-9.
3. Al-Omari WR, Sulaiman WR, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. *Int J Gynaecol Obstet* 2004;85:289-91.
4. American Society for Reproduction Medicine. Effectiveness and Treatment for unexplained infertility. A practice committee report, Brimngham: AL, 2000.
5. Amso NN, Ahuja KK, Morris N, Shaw RW. The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos. *Fertil Steril* 1990;53:1087-90.
6. Badawy A, Abdel Aal I, Abulatta M. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. *Fertil Steril* 2009;92:849-52.
7. Badawy A, Mosbah A, Shady M. Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial. *Fertil Steril* 2008;89:1209-12.
8. Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. *Clin Obstet Gynecol.* 2003;46:349-62.
9. Begum MR, Ferdous J, Begum A, Quadir E. Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. *Fertil Steril* 2009;92:853-7.
10. Bergh PA, Navot D. Ovarian hyperstimulation syndrome: a review of pathophysiology. *J Assist Reprod Genet* 1992;9:429-38.
11. Braat DD, Schoemaker R, Schoemaker J. Life table analysis of fecundity of intravenously gonadotropin hormonepatients with normogonadotropic and hypogonadotropic amenorrhea. *Fertil Steril* 1991;55:266-71.
12. Burkman RT, Tang MT, Malone KE, Marchbanks PA, McDonald JA, Folger SG, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. *Fertil Steril* 2003;79:852-4.
13. Chappel S, Kelton C, Nugent N. Expression of human gonadotrophins by recombinant DNA methods. In Genazzi A and Petraglia F(eds) *Proceedings of the 3rd World Congress on Gynecological Endocrinology*. Parthenon Publishing, Carnforth, 1992. p: 179-84.
14. Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin coadministration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. *Hum Reprod* 2006;21:1387-99.
15. D'Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. *Hum Reprod* 2002;17:2787-94.
16. Dadson WC, Hughes CL, Yancy SE, Haney AF. Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome. *Fertil Steril* 1989;52:915-8.
17. Deaton JL, Gibson M, Blackmer KM, Nakajima ST, Badger GJ. A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. *Fertil Steril* 1990;54:1083-8.

18. Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. *J Clin Endocrinol Metab* 1986;63:941-5.
19. Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Ferlini F, Perri T, et al. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle hormone. *Fertil Steril* 2003;80:390-7.
20. Filicori M, Flamigni C, Dellai P, Cognigni G, Michelacci L, Arnone R, et al. Treatment of anovulation with pulsatile gonadotropin hormone: prognostic factors and clinical results in 600 cycles. *J Clin Endocrinol Metab* 1994;79:1215-20.
21. Fluker MR, Urman B, MacKinnon M, Barrow SR, Pride SM, Ho Yuen B. Exogenous gonadotropin therapy in World Health Organization Groups I and II ovulatory disorders. *Obstet Gynecol* 1994;83:189-96.
22. Guzick DS, Zeleznik A. Efficacy of clomiphene citrate in the treatment of luteal phase deficiency: quantity versus quality of preovulatory follicles. *Fertil Steril* 1990;54:206-10.
23. Howles CM. Genetic engineering of human FSH (Gonal-F). *Hum Reprod Update* 1996;2:172-91.
24. Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for unexplained subfertility in women. *Cochrane Database Syst Rev* 2000;(3):CD000057.
25. Humaidan P, Quartarolo J, Evangelos G, Papanikolaou. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. *Fertil Steril* 2010;94:389-400.
26. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrhic infertility. *J Clin Endocrinol Metab* 1999;84:1617-22.
27. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrhic infertility. *J Clin Endocrinol Metab* 1998;83:2361-5.
28. Jansen RP. Pulsatile intravenous gonadotrophin releasing hormone for ovulation induction: determinants of follicular and luteal phase responses. *Hum Reprod* 1993;8(Suppl 2):193-6.
29. Kerin JF, Liu JH, Phillipou G, Yen SS. Evidence for a hypothalamic site of action of clomiphene citrate in women. *J Clin Endocrinol Metab* 1985;61:265-8.
30. Kettel LM, Roseff SJ, Berga SL, Mortola JF, Yen SS. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. *Fertil Steril* 1993;59:532-8.
31. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum anti-müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. *Hum Reprod* 2008;23:160-7.
32. Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM, et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. *Hum Reprod* 2002;17:2842-5.
33. Mannaerts B, Gordon K. Embryo implantation and GnRH antagonists: GnRH antagonist do not activate the GnRH receptor. *Hum Reprod* 2001;15:1882-3.
34. Martin KA, Hall JE, Adams JM, Crowley WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin hormone for induction of ovulation in hypo-gonadotropic amenorrhea. *J Clin Endocrinol Metab* 1963;77:125-9.
35. Mitwally MF, Casper RF. Aromatase inhibitors in ovulation induction. *Semin Reprod Med* 2004; 22: 61-78. Mitwally MF and Casper RF. Aromatase inhibition. *Reprod Technol* 2000;10:244-7.
36. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. *Am J Obstet Gynecol* 1998;159:210-5.
37. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. *Am J Epidemiol* 2002;155:217-24.
38. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. *Hum Reprod Update* 2002;8:270-90.
39. Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. *Hum Reprod* 2001;16:2263-6.
40. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. *Fertil Steril* 2006;85:112-20.
41. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaev V, Van Steirteghem A, et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. *Hum Reprod* 2005;20:636-41.
42. Reissmann T, Schally AV, Bouchard P, Riethmiller H, Engel J, et al. The LHRH antagonist cetrorelix: a review. *Hum Reprod Update* 2000;6:322-31.

43. Salat-Baroux J, Alvarez S, Antoine JM, Cornet D, Tibi C, Plachot M, et al. Treatment of hyperstimulation during in-vitro fertilization. *Hum Reprod* 1990;5:36-9.
44. Santoro N, Wierman ME, Filicori M, Waldstreicher J, Crowley WF Jr. Intravenous administration of pulsatile gonadotropin hormone in hypothalamic amenorrhea: effects of dosage. *J Clin Endocrinol Metab* 1986;62:109-16.
45. Sherman BM, Korenman SG. Measurement of plasma LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the short luteal phase. *J Clin Endocrinol Metab* 1974;38:89-93.
46. Sommer I, Zanger K, Dyong T, Dom C, Luckhaus J, Diedrich K, et al. Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women. *Eur J Endocrinol* 1994;131:280-5
47. Timmerman-van Kessel EC, Cikot RJ, Dargel-Donkers EJ, Zwertbroek W, van Dop PA, Schoot DC. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin hormone after gonadotropin hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome. *Fertil Steril* 2000;73:1145-8.
48. Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. *Fertil Steril* 2006;85:1761-5.
49. Wada I, Matson PL, Troup SA, Hughes S, Buck P, Lieberman BA. Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. *Hum Reprod* 1992;7:962-6.
50. Wada I, Matson PL, Troup SA, Morroll DR, Hunt L, Lieberman BA. Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition? *Br J Obstet Gynaecol* 1993;100:265-9.
51. Wu CH, Winkel CA. The effect of therapy initiation day on clomiphene citrate therapy. *Fertil Steril* 1989;52:564-8.